{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T00:12:22Z","timestamp":1793923942533,"version":"4.8.0"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.critrevonc.2018.11.008","type":"journal-article","created":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T12:50:34Z","timestamp":1543236634000},"page":"171-182","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":131,"special_numbering":"C","title":["Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life"],"prefix":"10.1016","volume":"133","author":[{"given":"Stefania","family":"Morganti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Tarantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7280-361X","authenticated-orcid":false,"given":"Giulia","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Trapani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno Achutti","family":"Duso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.critrevonc.2018.11.008_bib0005","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate Cancer","volume":"371","author":"Antonarakis","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2018.11.008_bib0010","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","author":"Atkinson","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.critrevonc.2018.11.008_bib0015","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ctrv.2016.08.004","article-title":"RNA-targeted therapeutics in cancer clinical trials: current status and future directions","volume":"50","author":"Barata","year":"2016","journal-title":"Cancer Treat. Rev."},{"issue":"4","key":"10.1016\/j.critrevonc.2018.11.008_bib0020","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.cell.2007.05.009","article-title":"High-resolution profiling of histone methylations in the human genome","volume":"129","author":"Barski","year":"2007","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2018.11.008_bib0025","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","article-title":"Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden","volume":"9","author":"Chalmers","year":"2017","journal-title":"Genome Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2018.11.008_bib0030","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jamaoncol.2016.1279","article-title":"Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast Cancer: a secondary analysis of the BOLERO-2 clinical trial","volume":"2","author":"Chandarlapaty","year":"2016","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2018.11.008_bib0035","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1158\/1078-0432.CCR-15-0943","article-title":"ESR1 mutations in circulating plasma tumor DNA from metastatic breast Cancer patients","volume":"22","author":"Chu","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"6378","key":"10.1016\/j.critrevonc.2018.11.008_bib0040","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1126\/science.aar3247","article-title":"Detection and localization of surgically resectable cancers with a multi-analyte blood test","volume":"359","author":"Cohen","year":"2018","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.critrevonc.2018.11.008_bib0045","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S1470-2045(15)00613-0","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phas","volume":"17","author":"Cristofanilli","year":"2016","journal-title":"Lancet Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2018.11.008_bib0050","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1093\/annonc\/mdu239","article-title":"Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle","volume":"25","author":"De Mattos-Arruda","year":"2014","journal-title":"Ann. Oncol."},{"issue":"8","key":"10.1016\/j.critrevonc.2018.11.008_bib0055","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nrg3767","article-title":"Expanding the computational toolbox for mining cancer genomes","volume":"15","author":"Ding","year":"2014","journal-title":"Nat. Rev. Genet."},{"issue":"9","key":"10.1016\/j.critrevonc.2018.11.008_bib0060","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1097\/JTO.0000000000000263","article-title":"Gefitinib Treatment in EGFR Mutated Caucasian NSCLC: Circulating-Free Tumor DNA as a Surrogate for Determination of EGFR Status","volume":"9","author":"Douillard","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2018.11.008_bib0065","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10549-010-1163-x","article-title":"HER2 status of circulating tumor cells in patients with metastatic breast cancer: a prospective, multicenter trial","volume":"124","author":"Fehm","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"10.1016\/j.critrevonc.2018.11.008_bib0070","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.molonc.2016.01.007","article-title":"Circulating tumor cell technologies","volume":"10","author":"Ferreira","year":"2016","journal-title":"Mol. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2018.11.008_bib0075","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S1367-5931(03)00082-6","article-title":"Ullrich A. Beyond Herceptin and gleevec","volume":"7","author":"Fischer","year":"2003","journal-title":"Curr. Opin. Chem. Biol."},{"issue":"suppl 5","key":"10.1016\/j.critrevonc.2018.11.008_bib0080","article-title":"Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Fizazi","year":"2015","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2018.11.008_bib0085","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa0900212","article-title":"Inhibition of poly(ADP-Ribose) polymerase in tumors from BRCA mutation carriers","volume":"361","author":"Fong","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2018.11.008_bib0090","unstructured":"Foundation Medicine\u2019s New Liquid Biopsy Assay Granted Breakthrough Device Designation by U.S. Food and Drug Administration | Foundation Medicine, Inc. 2018[http:\/\/investors.foundationmedicine.com\/news-releases\/news-release-details\/foundation-medicines-new-liquid-biopsy-assay-granted]."},{"key":"10.1016\/j.critrevonc.2018.11.008_bib0095","unstructured":"FRANCE M\u00c9DECINE G\u00c9NOMIQUE 2025. [https:\/\/www.gouvernement.fr\/sites\/default\/files\/document\/document\/2016\/06\/22.06.2016_remise_du_rapport_dyves_levy_-_france_medecine_genomique_2025.pdf]."},{"issue":"25","key":"10.1016\/j.critrevonc.2018.11.008_bib0100","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.2016.67.3061","article-title":"Plasma ESR1 mutations and the treatment of estrogen receptor\u2013Positive advanced breast Cancer","volume":"34","author":"Fribbens","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"Sep. (9)","key":"10.1016\/j.critrevonc.2018.11.008_bib0105","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/s41591-018-0134-3","article-title":"Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab","volume":"24","author":"Gandara","year":"2018","journal-title":"Nat. Med."},{"issue":"Aug. (302)","key":"10.1016\/j.critrevonc.2018.11.008_bib0110","article-title":"Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer","volume":"7","author":"Garcia-Murillas","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2018.11.008_bib0115","series-title":"The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur. Urol.","first-page":"178","article-title":"Management of patients with advanced prostate cancer","author":"Gillessen","year":"2018"},{"issue":"8","key":"10.1016\/j.critrevonc.2018.11.008_bib0120","doi-asserted-by":"crossref","first-page":"16010","DOI":"10.3390\/ijms140816010","article-title":"Non-coding RNAs: multi-tasking molecules in the cell","volume":"14","author":"Gomes","year":"2013","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.critrevonc.2018.11.008_bib0125","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nmeth.2562","article-title":"Computational approaches to identify functional genetic variants in cancer genomes","volume":"10","author":"Gonzalez-Perez","year":"2013","journal-title":"Nat. Methods"},{"issue":"7571","key":"10.1016\/j.critrevonc.2018.11.008_bib0130","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/526029a","article-title":"Human Genome Project: Twenty-five years of big biology","volume":"526","author":"Green","year":"2015","journal-title":"Nature"},{"issue":"7132","key":"10.1016\/j.critrevonc.2018.11.008_bib0135","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nature05610","article-title":"Patterns of somatic mutation in human cancer genomes","volume":"446","author":"Greenman","year":"2007","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.critrevonc.2018.11.008_bib0140","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1158\/1078-0432.CCR-13-1101","article-title":"Prognostic relevance of circulating tumor cells in blood and disseminated tumor cells in bone marrow of patients with squamous cell carcinoma of the oral cavity","volume":"20","author":"Gr\u00f6be","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.critrevonc.2018.11.008_bib0145","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1200\/JCO.2012.43.3755","article-title":"Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the sarah cannon research institute","volume":"31","author":"Hainsworth","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"15","key":"10.1016\/j.critrevonc.2018.11.008_bib0150","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.1158\/1078-0432.CCR-17-3102","article-title":"A first-in-Human study of the new oral selective estrogen receptor degrader AZD9496 for ER+\/HER2- advanced breast Cancer","volume":"24","author":"Hamilton","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.critrevonc.2018.11.008_bib0155","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1158\/0008-5472.CAN-12-4140","article-title":"Complex tumor genomes inferred from single circulating tumor cells by Array-CGH and next-generation sequencing","volume":"73","author":"Heitzer","year":"2013","journal-title":"Cancer Res."},{"issue":"22","key":"10.1016\/j.critrevonc.2018.11.008_bib0160","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1801946","article-title":"Nivolumab plus ipilimumab in lung Cancer with a high tumor mutational burden","volume":"378","author":"Hellmann","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2018.11.008_bib0165","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ccell.2018.04.001","article-title":"Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung Cancer","volume":"33","author":"Hellmann","year":"2018","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2018.11.008_bib0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncb3452","article-title":"The control of DNA repair by the cell cycle","volume":"19","author":"Hustedt","year":"2017","journal-title":"Nat. Cell Biol."},{"issue":"12","key":"10.1016\/j.critrevonc.2018.11.008_bib0175","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/annonc\/mdu480","article-title":"Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality?","volume":"25","author":"Ignatiadis","year":"2014","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2018.11.008_bib0180","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a012740","article-title":"Repair of strand breaks by homologous recombination","volume":"5","author":"Jasin","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"issue":"3","key":"10.1016\/j.critrevonc.2018.11.008_bib0185","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jmoldx.2017.01.011","article-title":"Guidelines for validation of next-generation sequencing\u2013Based oncology panels","volume":"19","author":"Jennings","year":"2017","journal-title":"J. Mol. Diagn."},{"issue":"7","key":"10.1016\/j.critrevonc.2018.11.008_bib0190","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1158\/1078-0432.CCR-13-2332","article-title":"Emergence of constitutively active estrogen receptor- mutations in pretreated advanced estrogen receptor-positive breast Cancer","volume":"20","author":"Jeselsohn","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2018.11.008_bib0195","first-page":"1972","article-title":"Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase","volume":"9","author":"Johnson","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2018.11.008_bib0200","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1158\/2326-6066.CIR-16-0143","article-title":"Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade","volume":"4","author":"Johnson","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"10","key":"10.1016\/j.critrevonc.2018.11.008_bib0205","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S1470-2045(13)70322-X","volume":"14","author":"Johnston","year":"2013","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2018.11.008_bib0210","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0092-8674(00)81333-1","article-title":"Lessons from hereditary colorectal cancer","volume":"87","author":"Kinzler","year":"1996","journal-title":"Cell"},{"issue":"7418","key":"10.1016\/j.critrevonc.2018.11.008_bib0215","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Koboldt","year":"2012","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.critrevonc.2018.11.008_bib0220","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1158\/1078-0432.CCR-08-2592","article-title":"Noninvasive detection of EGFR T790M in Gefitinib or erlotinib resistant non-small cell lung Cancer","volume":"15","author":"Kuang","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2018.11.008_bib0225","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","article-title":"Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia","volume":"152","author":"Landau","year":"2013","journal-title":"Cell"},{"issue":"6349","key":"10.1016\/j.critrevonc.2018.11.008_bib0230","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le DT","year":"2017","journal-title":"Science"},{"issue":"13","key":"10.1016\/j.critrevonc.2018.11.008_bib0235","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","article-title":"Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial","volume":"16","author":"Le Tourneau","year":"2015","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2018.11.008_bib0240","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.molonc.2014.12.003","article-title":"Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types","volume":"9","author":"Lebofsky","year":"2015","journal-title":"Mol. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2018.11.008_bib0245","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.cell.2008.03.029","article-title":"Highly integrated single-base resolution maps of the epigenome in Arabidopsis","volume":"133","author":"Lister","year":"2008","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.critrevonc.2018.11.008_bib0250","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nbt.2892","article-title":"Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer","volume":"32","author":"Lohr","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.critrevonc.2018.11.008_bib0255","doi-asserted-by":"crossref","DOI":"10.3390\/ijms17091505","article-title":"Circulating tumor cells (CTC) and cell-free DNA (cfDNA)workshop 2016: scientific opportunities and logistics for cancer clinical trial incorporation","author":"Lowes","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.critrevonc.2018.11.008_bib0260","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/0016-5085(93)90368-M","article-title":"Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review","volume":"104","author":"Lynch","year":"1993","journal-title":"Gastroenterology"},{"issue":"7057","key":"10.1016\/j.critrevonc.2018.11.008_bib0265","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/nature03959","article-title":"Genome sequencing in microfabricated high-density picolitre reactors","volume":"437","author":"Margulies","year":"2005","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.critrevonc.2018.11.008_bib0270","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/s41431-017-0081-3","article-title":"Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide French study","volume":"26","author":"Marino","year":"2018","journal-title":"Eur. J. Hum. Genet."},{"issue":"6","key":"10.1016\/j.critrevonc.2018.11.008_bib0275","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1158\/1055-9965.EPI-16-0889","article-title":"Estimation of the number of women living with metastatic breast Cancer in the United States. Cancer epidemiol","volume":"26","author":"Mariotto","year":"2017","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.critrevonc.2018.11.008_bib0280","doi-asserted-by":"crossref","DOI":"10.1200\/PO.17.00127","article-title":"Clinical utility of CLIA-Grade AR-V7 testing in patients with metastatic castration-resistant prostate Cancer","author":"Markowski","year":"2017","journal-title":"JCO Precis. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2018.11.008_bib0285","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrclinonc.2011.158","article-title":"Carcinomas of an unknown primary origin\u2014diagnosis and treatment","volume":"8","author":"Massard","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2018.11.008_bib0290","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","article-title":"High-throughput genomics and clinical outcome in hard-to-Treat advanced cancers: results of the MOSCATO 01 trial","volume":"7","author":"Massard","year":"2017","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.critrevonc.2018.11.008_bib0295","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/1078-0432.CCR-17-1181","article-title":"ESR1 methylation: a Liquid biopsy-based epigenetic assay for the follow up of patients with metastatic breast cancer receiving endocrine treatment","volume":"24","author":"Mastoraki","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2018.11.008_bib0300","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","author":"Mateo","year":"2018","journal-title":"Ann. Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2018.11.008_bib0305","doi-asserted-by":"crossref","first-page":"6856","DOI":"10.1158\/0008-5472.CAN-13-1197","article-title":"D538G mutation in estrogen receptor- : a novel mechanism for acquired endocrine resistance in breast Cancer","volume":"73","author":"Merenbakh-Lamin","year":"2013","journal-title":"Cancer Res."},{"issue":"7404","key":"10.1016\/j.critrevonc.2018.11.008_bib0310","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nature11156","article-title":"Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer","volume":"486","author":"Misale","year":"2012","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.critrevonc.2018.11.008_bib0315","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or platinum-pemetrexed in EGFR T790M-Positive lung Cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2018.11.008_bib0320","doi-asserted-by":"crossref","DOI":"10.1593\/tlo.12445","article-title":"Circulating cell-free DNA from colorectal Cancer patients may reveal high KRAS or BRAF mutation load","volume":"6","author":"Mouliere","year":"2013","journal-title":"Transl. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2018.11.008_bib0325","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S1097-2765(00)80202-6","article-title":"Brca1 controls homology-directed DNA repair","volume":"4","author":"Moynahan","year":"1999","journal-title":"Mol. Cell"},{"issue":"2","key":"10.1016\/j.critrevonc.2018.11.008_bib0330","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1097-2765(01)00174-5","article-title":"BRCA2 is required for homology-directed repair of chromosomal breaks","volume":"7","author":"Moynahan","year":"2001","journal-title":"Mol. Cell"},{"issue":"9","key":"10.1016\/j.critrevonc.2018.11.008_bib0335","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1097\/JTO.0b013e31825f2821","article-title":"Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA","volume":"7","author":"Nakamura","year":"2012","journal-title":"J. Thorac. Oncol."},{"issue":"14","key":"10.1016\/j.critrevonc.2018.11.008_bib0340","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1158\/1078-0432.CCR-13-2819","article-title":"Circulating tumor cells in patients with testicular germ cell tumors","volume":"20","author":"Nastaly","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2018.11.008_bib0345","series-title":"Non-Small Cell Lung Cancer","author":"National Comprehensive Cancer Network","year":"2018"},{"issue":"4260","key":"10.1016\/j.critrevonc.2018.11.008_bib0350","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1126\/science.959840","article-title":"The clonal evolution of tumor cell populations","volume":"194","author":"Nowell","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2018.11.008_bib0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmed.2017.10.007","article-title":"Characterization, Detection, and Treatment Approaches for Homologous Recombination Deficiency in Cancer","author":"O\u2019Kane","year":"2017","journal-title":"Trends Mol. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2018.11.008_bib0360","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.15252\/emmm.201404913","article-title":"Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease","volume":"7","author":"Olsson","year":"2015","journal-title":"EMBO Mol. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2018.11.008_bib0365","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1158\/1078-0432.CCR-13-2482","article-title":"Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA","volume":"20","author":"Oxnard","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"21","key":"10.1016\/j.critrevonc.2018.11.008_bib0370","doi-asserted-by":"crossref","first-page":"6384","DOI":"10.1158\/0008-5472.CAN-13-2030","article-title":"Real-time liquid biopsy in cancer patients: fact or fiction?","volume":"73","author":"Pantel","year":"2013","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2018.11.008_bib0375","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1158\/1078-0432.CCR-14-1913","article-title":"Development of circulating tumor cell-endocrine therapy index in patients with hormone receptor-positive breast Cancer","volume":"21","author":"Paoletti","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2018.11.008_bib0380","doi-asserted-by":"crossref","first-page":"9031","DOI":"10.1200\/JCO.2018.36.15_suppl.9031","article-title":"Economic impact of next generation sequencing vs sequential single-gene testing modalities to detect genomic alterations in metastatic non-small cell lung cancer using a decision analytic model","volume":"36","author":"Pennell","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2018.11.008_bib0385","doi-asserted-by":"crossref","DOI":"10.1186\/s12916-017-0840-6","article-title":"Emerging concepts in liquid biopsies","author":"Perakis","year":"2017","journal-title":"BMC Med."},{"key":"10.1016\/j.critrevonc.2018.11.008_bib0390","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju066","article-title":"Circulating tumor cells predict survival in early average-to-High risk breast Cancer patients","author":"Rack","year":"2014","journal-title":"JNCI J. Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.critrevonc.2018.11.008_bib0395","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/gm524","article-title":"Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine","volume":"6","author":"Raphael","year":"2014","journal-title":"Genome Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2018.11.008_bib0400","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.jtho.2016.05.036","article-title":"ctDNA determination of EGFR mutation status in european and japanese patients with advanced NSCLC: the ASSESS study","volume":"11","author":"Reck","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2018.11.008_bib0405","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1136\/gutjnl-2014-308859","article-title":"Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery","volume":"65","author":"Reinert","year":"2016","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.critrevonc.2018.11.008_bib0410","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.eururo.2012.01.017","article-title":"Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study","volume":"61","author":"Rink","year":"2012","journal-title":"Eur. Urol."},{"issue":"6230","key":"10.1016\/j.critrevonc.2018.11.008_bib0415","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non\u2013small cell lung cancer","volume":"348","author":"Rizvi","year":"2016","journal-title":"Science (80-.)"},{"issue":"12","key":"10.1016\/j.critrevonc.2018.11.008_bib0420","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/ng.2823","article-title":"Activating ESR1 mutations in hormone-resistant metastatic breast cancer","volume":"45","author":"Robinson","year":"2013","journal-title":"Nat. Genet."},{"issue":"6","key":"10.1016\/j.critrevonc.2018.11.008_bib0425","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa1706450","article-title":"Olaparib for metastatic breast Cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"10031","key":"10.1016\/j.critrevonc.2018.11.008_bib0430","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.critrevonc.2018.11.008_bib0435","doi-asserted-by":"crossref","first-page":"5463","DOI":"10.1073\/pnas.74.12.5463","article-title":"DNA sequencing with chain-terminating inhibitors","volume":"74","author":"Sanger","year":"1977","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.critrevonc.2018.11.008_bib0440","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1001\/jamaoncol.2016.1828","article-title":"Association of AR-V7 on circulating tumor cells as a treatment-specific biomarker with outcomes and survival in castration-resistant prostate Cancer","volume":"2","author":"Scher","year":"2016","journal-title":"JAMA Oncol."},{"issue":"313","key":"10.1016\/j.critrevonc.2018.11.008_bib0445","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac7551","article-title":"Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer","volume":"7","author":"Schiavon","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2018.11.008_bib0450","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1002\/ijc.28230","article-title":"Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma","volume":"133","author":"Schulze","year":"2013","journal-title":"Int. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2018.11.008_bib0455","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41698-017-0016-z","article-title":"Precision medicine: the foundation of future cancer therapeutics","volume":"1","author":"Shin","year":"2017","journal-title":"npj Precis. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2018.11.008_bib0460","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1038\/nm.3870","article-title":"Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients","volume":"21","author":"Siravegna","year":"2015","journal-title":"Nat. Med."},{"issue":"23","key":"10.1016\/j.critrevonc.2018.11.008_bib0465","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2018.11.008_bib0470","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1093\/annonc\/mdw192","article-title":"Consensus on precision medicine for metastatic cancers: a report from the MAP conference: table 1","volume":"27","author":"Swanton","year":"2016","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2018.11.008_bib0475","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","article-title":"Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial","volume":"18","author":"Swisher","year":"2017","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2018.11.008_bib0480","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0092-8674(83)90331-8","article-title":"The double-strand-break repair model for recombination","volume":"33","author":"Szostak","year":"1983","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.critrevonc.2018.11.008_bib0485","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/cge.13199","article-title":"Application of next\u2010generation sequencing to improve cancer management: a review of the clinical effectiveness and cost\u2010effectiveness","volume":"93","author":"Tan","year":"2018","journal-title":"Clin. Genet."},{"issue":"24","key":"10.1016\/j.critrevonc.2018.11.008_bib0490","doi-asserted-by":"crossref","first-page":"7808","DOI":"10.1158\/1078-0432.CCR-11-1712","article-title":"Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas","volume":"17","author":"Taniguchi","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2018.11.008_bib0495","unstructured":"The 100,000 Genomes Project, Genomics England. [https:\/\/www.genomicsengland.co.uk\/the-100000-genomes-project\/]."},{"issue":"5109","key":"10.1016\/j.critrevonc.2018.11.008_bib0500","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1126\/science.8484122","article-title":"Microsatellite instability in cancer of the proximal colon","volume":"260","author":"Thibodeau","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.critrevonc.2018.11.008_bib0505","unstructured":"TracerX | Tracking Cancer Evolution through study. [http:\/\/tracerx.co.uk\/]."},{"issue":"18_suppl","key":"10.1016\/j.critrevonc.2018.11.008_bib0510","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.18_suppl.LBA2553","article-title":"Precision medicine: clinical outcomes including long-term survival according to the pathway targeted and treatment period\u2013the IMPACT study","volume":"36","author":"Tsimberidou","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2018.11.008_bib0515","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1200\/JCO.2016.34.15_suppl.512","article-title":"Efficacy of palbociclib plus fulvestrant (P+F) in patients (pts) with metastatic breast cancer (MBC) and ESR1 mutations (mus) in circulating tumor DNA (ctDNA)","volume":"34","author":"Turner","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2018.11.008_bib0520","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/cam4.1372","article-title":"Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients","volume":"7","author":"Vanderwalde","year":"2018","journal-title":"Cancer Med."},{"issue":"12","key":"10.1016\/j.critrevonc.2018.11.008_bib0525","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1093\/annonc\/mdx545","article-title":"Clinical and molecular characterization of patients with cancer of unknown primary in the modern era","volume":"28","author":"Varghese","year":"2017","journal-title":"Ann. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.critrevonc.2018.11.008_bib0530","doi-asserted-by":"crossref","first-page":"12001","DOI":"10.1200\/JCO.2018.36.15_suppl.12001","article-title":"Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): interim B-F1RST results","volume":"36","author":"Velcheti","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2018.11.008_bib0535","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrclinonc.2009.237","article-title":"Microsatellite instability in colorectal cancer\u2014the stable evidence","volume":"7","author":"Vilar","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"6127","key":"10.1016\/j.critrevonc.2018.11.008_bib0540","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome lanscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science (80-.)"},{"issue":"1","key":"10.1016\/j.critrevonc.2018.11.008_bib0545","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrg2484","article-title":"RNA-Seq: a revolutionary tool for transcriptomics","volume":"10","author":"Wang","year":"2009","journal-title":"Nat. Rev. Genet."},{"issue":"11","key":"10.1016\/j.critrevonc.2018.11.008_bib0550","first-page":"1388","article-title":"Constitutively active human estrogen receptors containing amino acid substitutions for tyrosine 537 in the receptor protein","volume":"10","author":"Weis","year":"1996","journal-title":"Mol. Endocrinol."},{"issue":"5532","key":"10.1016\/j.critrevonc.2018.11.008_bib0555","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1126\/science.293.5532.1103","article-title":"Genes, genetics, and epigenetics: a correspondence","volume":"293","author":"Wu","year":"2001","journal-title":"Science (80-.)"},{"issue":"2","key":"10.1016\/j.critrevonc.2018.11.008_bib0560","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/annonc\/mdx766","article-title":"Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?","volume":"29","author":"Yang","year":"2018","journal-title":"Ann. Oncol."},{"issue":"127","key":"10.1016\/j.critrevonc.2018.11.008_bib0565","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1126\/scitranslmed.3003854","article-title":"Intratumor Heterogeneity : Seeing the Wood for the Trees Intratumor Heterogeneity : Seeing the Wood for the Trees","volume":"4","author":"Yap","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2018.11.008_bib0570","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1158\/0008-5472.CAN-12-0326","article-title":"Plastin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis","volume":"73","author":"Yokobori","year":"2013","journal-title":"Cancer Res."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818304220?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842818304220?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T15:59:07Z","timestamp":1764863947000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842818304220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":114,"alternative-id":["S1040842818304220"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2018.11.008","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2018.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}